We chose to study the possible differentiated therapeutic activity of TPST-1495 in the spontaneous APCmin/+ model of polyposis and colorectal cancer for several reasons, which we posit underline the importance of dual EP2 and EP4 receptor blockade: (i) prostaglandin signaling is known to be a significant driver of colorectal cancer; (ii) the APCmin/+ model is spontaneous and less inflammatory than conventional implanted syngeneic tumor cells; and (iii) early clinical development involves studies in advanced patients that are refractory to or become refractory to immune checkpoint inhibition. Here, PTGER2 is linked to polyposis.